TaqMan Oncology Multiplex Positive Control, 10% VAF

The Applied Biosystems TaqMan Oncology Multiplex Positive Control, 10% VAF, is a specialized positive control reference material designed for liquid biopsy analysis of actionable cancer biomarkers. This control material is carefully formulated to contain actionable cancer biomarker at a standardized 10% variant allele frequency (VAF) across multiple genes, including BRAF, EGFR, KRAS, PIK3CA, and ESR1. The product enables translational researchers and molecular pathologists to help ensure workflow integrity and help provide confidence in analytical research results.

Specifically designed for compatibility with TaqMan Oncology dPCR Multiplex kits, this positive control facilitates a turnkey solution when implemented on the QuantStudio Absolute Q dPCR System, offering a comprehensive quality control framework for oncology biomarker detection workflows.

Features of the TaqMan Oncology Multiplex Positive Control, 10% VAF, include:

• Ready-to-use format—carefully formulated positive control delivered in a ready-to-use configuration that enables a streamlined pipette-and-go workflow, reducing preparation steps and hands-on time
• Wet lab verified performance—comprehensive wet laboratory testing conducted on the Absolute Q dPCR System to verify product characteristics and help ensure analytical reliability
• Lot-to-lot reproducibility—manufactured using stringent Thermo Fisher Scientific manufacturing processes designed to deliver consistent and reproducible results across production lots

Optimized ready-to-use formulation for liquid biopsy applications

This positive control has been specifically formulated with liquid biopsy analysis requirements in mind, delivering a ready-to-use format that helps reduce the need for additional preparation steps. The control is engineered to accurately emulate the characteristics of fragmented DNA that would typically be extracted from appropriate plasma samples to facilitate experimental conditions that closely mirror real-world clinical specimens. This design consideration is critical for liquid biopsy workflows, where the integrity and fragmentation patterns of circulating cell-free DNA directly impact assay performance and downstream analytical results.

Streamlined integration with biomarker assay workflows

The implementation of this positive control follows a straightforward protocol that integrates easily with existing biomarker assay procedures. Users simply incorporate the positive control as instructed within their specific biomarker assay protocols, maintaining consistency with established laboratory workflows. The control is then pipetted directly into the MAP16 plate, which has been designed to accommodate the precise volumetric requirements of the assay system while helping ensure optimal sample distribution and processing efficiency.

Compatible platform integration with Absolute Q system

The positive control demonstrates compatibility with the Absolute Q platform, enabling direct execution of assays without requiring additional instrumentation or protocol modifications. Once the control has been properly loaded into the MAP16 plate according to the specified instructions, the entire assembly can be processed directly on the Absolute Q system. This easy integration helps support quality control measures that can be implemented without disrupting established analytical workflows or requiring specialized handling procedures that might introduce additional sources of variability into the experimental process.